Efficacy of Enasidenib

Various findings with Enasidenib suggest that it has been designed to allosterically inhibit mutated IDH2 to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The effectiveness of ensidipine has been demonstrated in a single-arm trial in 199 patients with relapsed or refractory acute myeloid leukemia who had IDH2 mutations detected by real-time IDH2 analysis.

The trial measured the percentage of patients with no evidence of disease who had complete recovery of blood counts after treatment (complete response or CR) and the percentage of patients who had no evidence of disease and had partial recovery of blood counts after treatment (complete response with partial hematologic recovery or CRh). After at least 6 months of treatment, 19% of patients experienced a mean CR of 8.2 months, and 4% experienced a mean CRh of 9.6 months. Of the 157 patients who required blood or platelet transfusions for acute myeloid leukemia at the start of the study, 34% no longer required transfusions after receiving ensidipine.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.